.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Non-valvular atrial fibrillation (NVAF) remains a significant clinical challenge for cardiologists worldwide. Research suggests that vildagliptin for atrial fibrillation may offer a novel therapeutic approach by protecting heart cells. Specifically, this dipeptidyl peptidase-4 (DPP-4) inhibitor shows potential in reducing inflammatory damage and programmed cell death. A recent 2026 study highlights the importance of specific signaling pathways in this process. Therefore, understanding these mechanisms is vital for developing better cardiovascular treatments.
Vildagliptin works by modulating the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) pathway. In a recent rat model, researchers found that vildagliptin for atrial fibrillation significantly improved cardiac electrical stability. Furthermore, the drug increased levels of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP). These molecules are essential for maintaining proper heart rhythm and vascular tone. Consequently, vildagliptin helps restore the balance of signaling proteins in the heart tissue.
The study compared a drug-treated group with a control group of rats with induced atrial fibrillation. Notably, the treatment group showed a longer effective refractory period (ERP) and action potential duration (APD90). Moreover, vildagliptin significantly reduced the cardiomyocyte apoptosis index (AI) and the expression of inflammatory cytokines. Researchers also observed a downregulation of phosphodiesterase 5A (PDE5A). Ultimately, these changes suggest that vildagliptin protects the heart by preventing harmful structural remodeling.
Vildagliptin reduces inflammation and cardiomyocyte apoptosis. It achieves this by modulating the NO/sGC/cGMP signaling pathway and downregulating PDE5A, which improves cardiac electrical stability.
The primary pathway involved is the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) signaling system. Vildagliptin enhances this pathway to protect heart tissue.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Wang Z et al. Vildagliptin alleviates cardiomyocyte apoptosis and inflammatory responses in the treatment of non-valvular atrial fibrillation by regulating the NO/sGC/cGMP signaling pathway. Immunopharmacol Immunotoxicol. 2026 Apr 29. doi: 10.1080/08923973.2026.2639559. PMID: 42056726.
Liu X, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. BMC Cardiovasc Disord. 2017;17(1):159.
Nicotera R, et al. Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on parameters of glucose metabolism and vascular markers. MDPI. 2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Vildagliptin shows potential in treating non-valvular atrial fibrillation by reducing inflammation and apoptosis via the NO/sGC/cGMP signaling pathway....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
